---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-239127"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2023-09-21T23:59:59+00:00"
generated_at: "2026-06-10T10:58:47.440065+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma reports FY2023 net loss of $19.6M; FDA cleared BB-301 IND; completed $30.9M offering

## Summary
- Net loss $19.6M ($14.12/share) vs $18.2M ($37.88/share) prior year; cash $2.5M at June 30, 2023.
- FDA cleared IND for BB-301 for OPMD in June 2023; 15 subjects enrolled in Natural History Study as of September.
- Closed $30.9M public offering in August 2023 to fund BB-301 clinical development and operations.
- R&D expenses $12.8M (up from $11.3M); expect to dose first BB-301 patient in 2H2023 with interim data in 12 months.

## SEC filing metadata
- accession: 0001193125-23-239127
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2023-09-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312523239127/0001193125-23-239127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312523239127/d498664d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-239127
- JSON: https://secwatch.observer/filing/0001193125-23-239127.json
- Plain text: https://secwatch.observer/filing/0001193125-23-239127.txt

## Key facts
- Earnings Releases
  Benitec Biopharma Inc. reported financial results for the fiscal year ended June 30, 2023.
  - Period: the fiscal year ended June 30, 2023
  - Result: reported results
  source text: On September 21, 2023, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal year ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312523239127/0001193125-23-239127-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.